Last updated: September 4, 2026
Sapanisertib, also known as TAK-228 and INK128, remains an investigational oral mTORC1/mTORC2 inhibitor with no FDA approval, no commercial sales, and no Orange Book listing. Takeda-led clinical development generated activity across renal cell carcinoma, endometrial cancer, breast cancer, multiple myeloma, prostate cancer and other solid tumors, but the program has not produced a regulatory filing or an approved indication. The commercial outlook is therefore highly constrained: base-case value is limited to licensing, pipeline optionality or research use unless a new sponsor restarts development with a differentiated combination strategy.
What is sapanisertib and how does it work?
Sapanisertib is an orally administered, ATP-competitive inhibitor of mechanistic target of rapamycin complex 1 and complex 2, commonly abbreviated mTORC1 and mTORC2. It was developed to inhibit the mTOR pathway more broadly than rapamycin analogs such as everolimus, which primarily inhibit mTORC1.
| Attribute |
Sapanisertib |
| Generic name |
Sapanisertib |
| Development codes |
TAK-228, INK128, MLN0128 |
| Drug class |
ATP-competitive mTORC1/mTORC2 inhibitor |
| Route |
Oral |
| Primary disease strategy |
Oncology |
| Original developer |
Intellikine |
| Later developer |
Takeda |
| FDA approval |
None identified |
| Commercial status |
No marketed product |
| Orange Book status |
No listed product patent because no approved product |
| Biosimilar relevance |
None; sapanisertib is a small molecule |
| Current commercial revenue |
None from approved product sales |
The scientific rationale was to suppress both mTORC1 signaling, which regulates protein synthesis and cell growth, and mTORC2 signaling, which affects AKT activation, survival and metabolism. The strategy was intended to address resistance mechanisms that can emerge with rapamycin-based therapy.
What is the current development status of sapanisertib?
Sapanisertib has remained in clinical development rather than advancing to a marketed product. Publicly reported studies evaluated the drug as monotherapy and in combinations with endocrine therapy, chemotherapy, immunotherapy and other targeted agents.
Key development areas included:
| Indication or setting |
Development rationale |
Commercial assessment |
| Advanced renal cell carcinoma |
Target mTOR signaling after prior VEGF-directed treatment or mTOR inhibitor exposure |
High competitive pressure from immunotherapy and VEGF/mTOR combinations |
| Endometrial cancer |
Target PI3K/AKT/mTOR pathway alterations and hormonal resistance |
Potential biomarker niche, but limited by combination tolerability |
| HR-positive breast cancer |
Combine with exemestane or fulvestrant to reverse endocrine resistance |
Large market, but crowded by CDK4/6, PI3K and AKT inhibitors |
| Multiple myeloma |
Combine with pomalidomide and dexamethasone |
Competitive disease area with many later-line agents |
| Prostate cancer |
Target PI3K/AKT/mTOR signaling and treatment resistance |
Strong competition from androgen-receptor pathway drugs |
| Other solid tumors |
Explore pathway dependence or combination sensitivity |
Generally insufficient differentiation without a predictive biomarker |
The development program produced clinical signals in selected settings, but the evidence did not establish a clear registration path. Broad mTOR inhibition has been limited by class toxicities, including hyperglycemia, mucositis, rash, fatigue, diarrhea and cytopenias. Combination regimens increased the risk of dose interruptions and treatment discontinuation.
ClinicalTrials.gov records identify multiple sapanisertib studies, including early- and mid-stage trials involving solid tumors and hematologic malignancies. The program has not progressed to an FDA-approved new drug application based on those studies (National Library of Medicine, n.d.).
Has sapanisertib been approved by the FDA?
No. Sapanisertib has not received FDA approval for cancer or any other indication based on FDA approval records and publicly available drug information through the latest established development period.
The regulatory position is:
| Regulatory question |
Status |
| FDA approval |
No |
| New drug application approval |
None identified |
| Approved indication |
None |
| FDA-labeled dosage |
None |
| REMS program |
None identified |
| Orange Book listing |
None |
| Generic approval pathway |
Not available |
| Reference-listed drug |
None |
Because sapanisertib has no approved reference product, generic manufacturers cannot file an abbreviated new drug application referencing an FDA-approved sapanisertib product. Any future competitor would need to address the regulatory requirements applicable to an unapproved investigational drug, unless an innovator product is first approved.
What patents protect sapanisertib?
Sapanisertib is protected, or was intended to be protected, by composition-of-matter, pharmaceutical composition, formulation and method-of-use patent families originating from Intellikine and later associated with Takeda. The exact live status of each family depends on jurisdiction, terminal disclaimers, patent-term adjustment, maintenance fees and prosecution history.
The commercially important patent categories are:
Composition-of-matter patents
These cover the sapanisertib chemical structure and related analogs. Composition claims usually provide the strongest protection because they can cover use of the molecule across multiple indications and formulations.
For a compound discovered in the late 2000s, unadjusted U.S. patent expiry would generally fall in the late 2020s or early 2030s, depending on the earliest effective nonprovisional filing date and patent-term adjustment. No reliable commercial conclusion should be drawn from a publication date alone.
Pharmaceutical composition patents
These cover drug compositions containing sapanisertib, including excipients, solid forms or specific dosage presentations. Such patents can extend protection beyond a basic compound patent but are more vulnerable to validity and design-around challenges.
Method-of-use patents
Clinical development generated potential use claims for cancer treatment, including:
- Treating renal cell carcinoma.
- Treating endometrial cancer.
- Treating breast cancer.
- Combining sapanisertib with endocrine therapy.
- Combining sapanisertib with immunotherapy or targeted agents.
- Treating tumors with pathway alterations involving PI3K, AKT or mTOR signaling.
Method-of-use patents generally have narrower enforcement value than composition claims. Their commercial value depends on whether the patented indication becomes the approved label and whether the prescribing behavior is readily detectable.
Formulation and manufacturing patents
Potential protection can also cover oral dosage forms, polymorphs, crystalline forms, granulation methods and manufacturing processes. These rights may create manufacturing barriers, but they do not necessarily prevent a competitor from producing a non-infringing formulation.
No Orange Book-listed patent estate exists because sapanisertib has no approved product. The absence of an Orange Book listing does not mean that all underlying patent families have expired or lack enforceability. It means only that no approved reference product has generated an Orange Book patent listing.
When does sapanisertib lose exclusivity?
Sapanisertib has no operative FDA market exclusivity period because it has never been approved. The relevant legal distinction is between regulatory exclusivity and patent protection.
| Exclusivity type |
Sapanisertib status |
| New chemical entity exclusivity |
Not triggered because no approval |
| Orphan-drug exclusivity |
No approved orphan indication identified |
| Pediatric exclusivity |
None identified |
| FDA listed-drug exclusivity |
None |
| Patent exclusivity |
Depends on individual patent families and jurisdiction |
| Hatch-Waxman Paragraph IV exposure |
No ANDA pathway while no reference product exists |
If approved in the future, sapanisertib could potentially receive new chemical entity exclusivity if the statutory requirements were satisfied. Earlier investigational use does not itself start the five-year NCE exclusivity period. A future approval could also qualify for other regulatory protections depending on the indication and clinical development record.
Have companies filed Paragraph IV challenges against sapanisertib?
No meaningful Paragraph IV challenge has been identified. The reason is structural: Paragraph IV litigation normally arises when a generic applicant files an ANDA referencing an approved listed drug and certifies that one or more listed patents are invalid, unenforceable or not infringed.
Sapanisertib has no approved reference-listed drug and no Orange Book patent listing. The more realistic future challenge scenarios would be:
- A future approval creates an Orange Book listing.
- A generic applicant files an ANDA with a Paragraph IV certification.
- The sponsor sues within the statutory period.
- FDA approval is potentially stayed for up to 30 months, subject to statutory exceptions and litigation outcomes.
A pre-approval patent dispute could still arise through a declaratory-judgment action, patent opposition, inter partes review or a manufacturing dispute, but that would not be a conventional Paragraph IV case.
What patent litigation affects sapanisertib?
No major public patent litigation has established a commercial barrier around an approved sapanisertib product. The more important legal risk is inactive or declining patent value rather than active generic litigation.
Patent strength is best assessed by claim scope, remaining term, prosecution history and clinical relevance:
| Patent layer |
Relative strength |
Main weakness |
| Core composition |
High if valid and unexpired |
Prior-art and obviousness risk |
| Salt or polymorph |
Medium |
Design-around potential |
| Formulation |
Medium to low |
Alternative excipients or dosage forms |
| Monotherapy use |
Medium |
Narrow clinical applicability |
| Combination use |
Low to medium |
Label and prescribing-behavior proof |
| Manufacturing process |
Medium |
Non-infringing process alternatives |
The absence of litigation should not be interpreted as evidence of a strong estate. It may instead reflect the absence of an approved product, generic market and commercial sales opportunity.
What is the commercial market for sapanisertib?
Sapanisertib has no current commercial market as an approved therapy. Its addressable market would depend on the selected indication and whether the drug could show a therapeutic advantage over established mTOR, PI3K, AKT, CDK4/6, immunotherapy and antibody-drug conjugate options.
Renal cell carcinoma
Renal cell carcinoma is a substantial oncology market, but treatment has shifted toward immune checkpoint inhibitors and VEGF-directed combinations. Everolimus remains an established mTOR comparator, while newer regimens compete on survival, tolerability and sequencing flexibility.
Sapanisertib would need to demonstrate one or more of the following:
- Superior progression-free or overall survival.
- Activity after modern immunotherapy and VEGF therapy.
- A biomarker-defined responder population.
- Better tolerability than everolimus.
- A combination profile that does not materially increase metabolic or hematologic toxicity.
Without that differentiation, broad RCC adoption would be difficult.
Endometrial cancer
Endometrial cancer offers a more plausible biomarker strategy because PI3K/AKT/mTOR alterations are common. The market is still competitive, with immunotherapy, lenvatinib combinations, hormonal therapy and targeted approaches occupying treatment lines.
A focused development program could target patients with pathway alterations or endocrine-sensitive disease. The commercial opportunity would likely be narrower than an all-comer indication.
HR-positive breast cancer
The breast cancer market is large, but the competitive standard has moved rapidly. CDK4/6 inhibitors, PI3K inhibitors, AKT inhibitors, oral selective estrogen receptor degraders and antibody-drug conjugates create a high evidence threshold.
Sapanisertib would likely require a biomarker-selected or resistance-specific indication. A broad endocrine-resistance label would face substantial reimbursement and prescribing barriers.
What is the projected market size for sapanisertib?
A conventional revenue forecast is not supportable because the drug lacks approval, a defined launch date, a registrational trial, a commercial partner and a current label. A scenario framework is more appropriate.
| Scenario |
Development assumption |
Commercial outcome |
| Base case |
No material restart of late-stage development |
$0 product revenue |
| Restart case |
New sponsor funds biomarker-led Phase 2 development |
Limited asset value and licensing potential |
| Approval case |
Positive registrational trial in a defined oncology niche |
Potential peak sales in the low hundreds of millions of dollars, depending on label and pricing |
| Broad success case |
Differentiated activity across several tumor types |
Higher upside, but low probability given competition and prior development history |
The base case remains zero commercial revenue. A restart would probably require a low acquisition price, access to existing clinical data, a clear biomarker hypothesis and a combination partner. A large upfront transaction would be difficult to justify without new clinical evidence.
How does sapanisertib compare with everolimus and other mTOR inhibitors?
| Drug |
Target profile |
Approval status |
Commercial position |
| Sapanisertib |
mTORC1/mTORC2 |
Investigational |
No sales |
| Everolimus |
Primarily mTORC1 |
FDA approved in multiple indications |
Established oncology and specialty product |
| Temsirolimus |
mTORC1 |
FDA approved for advanced RCC |
Smaller, intravenous market |
| Ridaforolimus |
mTOR pathway |
Limited historical development |
No comparable current position in broad oncology |
| AZD2014/vistusertib |
mTORC1/mTORC2 |
Investigational |
Development challenges similar to class |
| PI3K/AKT inhibitors |
Upstream or adjacent pathway targets |
Several approved or developed |
Competitive alternatives |
Sapanisertib’s theoretical advantage is broader pathway inhibition. Its commercial disadvantage is that broader inhibition can increase toxicity and may not translate into a sufficient efficacy advantage.
What licensing deals involve sapanisertib?
Intellikine discovered and advanced the INK128 program before Takeda acquired Intellikine in 2011. The transaction transferred Intellikine’s oncology pipeline, including the mTOR program, to Takeda. Sapanisertib was subsequently developed under Takeda designations including TAK-228 and MLN0128.
No major commercialization license has established a separate marketed franchise for sapanisertib. The principal strategic transaction remains Takeda’s acquisition of Intellikine rather than a late-stage regional licensing deal.
What generic entry risks exist?
Immediate generic entry risk is low because there is no approved product. Long-term commercial risk would become high if sapanisertib were approved without robust composition-of-matter protection extending through the expected launch period.
The main future entry routes would be:
- Paragraph IV ANDA litigation after Orange Book listing.
- Patent expiration followed by ANDA entry.
- A competing small-molecule mTOR inhibitor.
- Off-label substitution if clinical guidelines adopt another mTOR-pathway agent.
- New targeted therapies that displace the proposed indication.
Because sapanisertib is a small molecule, biosimilar competition is irrelevant. The relevant barriers are patents, clinical differentiation, manufacturing know-how, regulatory exclusivity and payer positioning.
Key Takeaways
- Sapanisertib is an investigational oral mTORC1/mTORC2 inhibitor, also known as TAK-228, INK128 and MLN0128.
- It has no FDA approval, no approved label, no Orange Book listing and no commercial product revenue.
- Clinical development covered RCC, endometrial cancer, breast cancer, multiple myeloma, prostate cancer and other tumors.
- The principal scientific risk is whether dual mTOR inhibition can deliver superior efficacy without unacceptable class toxicity.
- No conventional Paragraph IV litigation has emerged because there is no approved reference product.
- Composition, formulation, method-of-use and manufacturing patent families may exist, but their commercial value depends on jurisdiction, remaining term and claim validity.
- The base-case market projection is zero revenue unless a sponsor restarts development.
- A successful restart would most likely require a biomarker-led oncology strategy rather than an all-comer indication.
- Everolimus, PI3K/AKT inhibitors, CDK4/6 inhibitors, immunotherapies and targeted combinations create substantial competitive pressure.
- The asset has greater potential licensing or research value than near-term commercial product value.
FAQs
Is sapanisertib the same as everolimus?
No. Sapanisertib is an ATP-competitive inhibitor designed to inhibit mTORC1 and mTORC2. Everolimus is a rapamycin analog that primarily inhibits mTORC1.
Can a generic version of sapanisertib launch now?
No conventional generic launch pathway exists because sapanisertib has no FDA-approved reference product and no Orange Book listing.
Is sapanisertib a biologic or a small molecule?
Sapanisertib is an orally administered small molecule. Biosimilar regulation does not apply.
What company owns sapanisertib?
The program originated at Intellikine and was acquired by Takeda. Takeda has been the principal sponsor associated with the TAK-228 development program.
What would make sapanisertib commercially viable?
The strongest route would be a biomarker-selected indication with confirmed clinical benefit, manageable toxicity, a defensible composition patent term and a combination strategy that improves outcomes over established mTOR and immuno-oncology regimens.
References
-
Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
-
National Library of Medicine. (n.d.). ClinicalTrials.gov. U.S. National Library of Medicine.
-
National Cancer Institute. (n.d.). Sapanisertib. NCI Drug Dictionary. National Institutes of Health.
-
Takeda Pharmaceutical Company Limited. (2011). Takeda to acquire Intellikine and its portfolio of novel oncology compounds. Takeda.
-
World Health Organization. (n.d.). Sapanisertib: International nonproprietary name. World Health Organization.
